Anika Therapeutics (ANIK) Non-Current Deferred Tax Liability (2010 - 2023)

Anika Therapeutics (ANIK) has 14 years of Non-Current Deferred Tax Liability data on file, last reported at $2.0 million in Q3 2023.

• On a quarterly basis, Non-Current Deferred Tax Liability fell 71.25% year-over-year to $2.0 million in Q3 2023; TTM through Sep 2023 was $2.0 million, a 71.25% decrease from a year earlier, with the FY2022 full-year figure at $6.4 million, down 36.63% from the prior year.
• Non-Current Deferred Tax Liability for Q3 2023 stood at $2.0 million, down from $3.2 million in the prior quarter.
• Over the last five years, Non-Current Deferred Tax Liability for ANIK reached as high as $16.0 million in Q1 2020 and fell as low as $2.0 million in Q3 2023.
• Historically, Non-Current Deferred Tax Liability has averaged $8.4 million across 5 years, with a median of $8.2 million in 2022.
• Across the five-year window, Non-Current Deferred Tax Liability surged 373.14% in 2020 and tumbled 71.25% in 2023, its largest moves.
• Year by year, Non-Current Deferred Tax Liability stood at $4.3 million in 2019, then soared by 174.65% to $11.9 million in 2020, then dropped by 14.61% to $10.2 million in 2021, then tumbled by 36.63% to $6.4 million in 2022, then tumbled by 69.62% to $2.0 million in 2023.
• Per Business Quant data, the three most recent Non-Current Deferred Tax Liability figures were $2.0 million in Q3 2023, $3.2 million in Q2 2023, and $4.1 million in Q1 2023.